Research dossier
Clinical research on Vitamin E
11 trials reviewed across 4 indications.
Strongest evidence
General health
Mechanism
Vitamin E is the principal lipid-soluble antioxidant, protecting cell membranes from oxidative damage. Frank deficiency, which is rare, causes hemolytic anemia and neurological symptoms.
Adequate vitamin E intake is required for normal physiology, but most people get enough from food. Routine high-dose supplementation does not improve general-health outcomes and at 400 IU/day or higher is associated with a small increase in all-cause mortality. The case for vitamin E supplements in healthy adults is weak.
Best obtained from food (nuts, seeds, vegetable oils). Supplementing at 400 IU/day or higher is not recommended.
Trials cited
Miller meta-analysis — high-dose vitamin E and all-cause mortality
negative · Meta-analysis
Miller et al., 2005, Annals of Internal Medicine (PMID 15537682)n=135967Meta-analysis of 19 randomized trials totaling 135,967 participants. Vitamin E at doses of 400 IU/day or higher was associated with a statistically significant 4% increase in all-cause mortality. Lower doses showed no clear effect. Headline conclusion that pushed many guidelines to recommend against high-dose supplementation.
Mortality increase was modest in absolute terms but consistent enough to drive guideline change. Defenders argue trial heterogeneity, but the result has not been overturned.
Bjelakovic antioxidant meta-analysis — mortality from supplemental antioxidants
negative · Meta-analysis
Bjelakovic et al., 2007, JAMA (PMID 17327526)n=232606Bayesian meta-analysis of 68 antioxidant trials. Vitamin E was associated with a 4% increase in all-cause mortality, consistent with Miller 2005. Beta-carotene and vitamin A also showed mortality increases. The antioxidant cancer-prevention hypothesis collapsed in pooled data.
Trial heterogeneity remains a defender argument, but the directional signal across multiple meta-analyses is consistent.
Cognition and Alzheimer's
Mechanism
High-dose vitamin E may reduce oxidative damage in neurons of patients with established Alzheimer's pathology. The mechanism does not appear to translate to prevention or to cognition in healthy adults.
Two trials (Sano 1997, TEAM-AD 2014) at 2,000 IU/day showed modest slowing of functional decline in established Alzheimer's, but cognitive scores did not improve. The Petersen 2005 MCI trial was null — vitamin E does not prevent progression from MCI to AD. There is no clean evidence for vitamin E in cognition outside established AD.
May be considered as adjunct in established Alzheimer's under physician supervision. Does not prevent dementia and does not improve cognition in healthy adults.
Sano — high-dose vitamin E for moderate Alzheimer's
positive · RCT
Sano et al., 1997, NEJM (PMID 9110909)n=341High-dose vitamin E (2,000 IU/day) modestly delayed time to functional decline in moderate Alzheimer's patients vs placebo. One of the few vitamin E trials with a positive primary endpoint, applied to established disease rather than prevention.
Small (n=341), restricted to moderate AD, used a very high 2,000 IU dose. Cognitive scores themselves did not improve — the benefit was in delaying functional decline. Effect modest.
TEAM-AD — vitamin E for mild-to-moderate Alzheimer's
positive · RCT
Dysken et al., 2014, JAMA (PMID 24381967)n=613Replication-style trial of vitamin E in mild-to-moderate AD. 2,000 IU/day slowed functional decline by approximately 19% vs placebo over a little more than two years. Combined with Sano 1997, this is the strongest case for vitamin E in established Alzheimer's.
Veteran population (almost all male). High dose. Effect is on functional decline, not cognition itself. Specific to established AD, not prevention or general cognition.
Petersen — vitamin E for mild cognitive impairment
Null · RCT
Petersen et al., 2005, NEJM (PMID 15829527)n=769Tested whether high-dose vitamin E could prevent progression from MCI to AD. Three-year trial in nearly 800 adults showed no reduction in conversion to AD. Vitamin E does not work as Alzheimer's prevention.
Same dose as Sano 1997 but applied earlier in the disease course. The fact that it worked modestly in moderate AD but not in MCI is unusual and not well understood.
Cancer prevention
Mechanism
The antioxidant hypothesis predicted that vitamin E would reduce oxidative DNA damage and cancer incidence. The hypothesis failed in trials.
SELECT (n=35,533) showed alpha-tocopherol increased prostate cancer in men by 17%. ATBC and pooled meta-analyses found no cancer prevention benefit. Routine vitamin E supplementation for cancer prevention is not supported and is associated with harm in men's prostate cancer.
Men should not take supplemental high-dose alpha-tocopherol as a cancer-prevention strategy. SELECT showed harm.
SELECT — selenium and vitamin E for prostate cancer
negative · RCT
Klein et al., 2011, JAMA (PMID 21990298)n=35533The largest prostate cancer prevention trial ever conducted. Over 35,000 men randomized to vitamin E, selenium, both, or placebo. Vitamin E increased prostate cancer incidence by 17% over extended follow-up. The hypothesis was that antioxidants would reduce cancer; the trial showed the opposite.
Used the synthetic dl-alpha-tocopherol form, which some defenders argue differs from natural d-alpha-tocopherol. Dose was 400 IU/day, the same range as most consumer supplements. Harm signal is hard to dismiss.
ATBC — alpha-tocopherol and beta-carotene in male smokers
Null · RCT
ATBC Cancer Prevention Study Group, 1994, NEJM (PMID 8127329)n=29133Large prevention trial in Finnish male smokers. Vitamin E at 50 mg/day showed no benefit on lung cancer incidence and a borderline increase in hemorrhagic stroke. (The companion beta-carotene arm caused harm.)
Lower vitamin E dose than later HOPE/SELECT trials, but the directional signal — no benefit, possible bleeding harm — was already visible.
Bjelakovic antioxidant meta-analysis — mortality from supplemental antioxidants
negative · Meta-analysis
Bjelakovic et al., 2007, JAMA (PMID 17327526)n=232606Bayesian meta-analysis of 68 antioxidant trials. Vitamin E was associated with a 4% increase in all-cause mortality, consistent with Miller 2005. Beta-carotene and vitamin A also showed mortality increases. The antioxidant cancer-prevention hypothesis collapsed in pooled data.
Trial heterogeneity remains a defender argument, but the directional signal across multiple meta-analyses is consistent.
Cardiovascular disease prevention
Mechanism
Vitamin E was hypothesized to reduce LDL oxidation, atherogenesis, and cardiovascular events. Multiple large trials at 300–600 IU/day failed to confirm benefit.
HOPE, HOPE-TOO, GISSI-Prevenzione, and the Women's Health Study together randomized over 67,000 adults to vitamin E and found no reduction in cardiovascular events. HOPE-TOO showed a 19% increase in heart failure hospitalization. The cardiovascular hypothesis is refuted at meaningful endpoints.
Routine vitamin E for cardiovascular prevention is not supported by randomized evidence and may worsen heart failure risk in high-risk patients.
HOPE — vitamin E for cardiovascular disease prevention
Null · RCT
Yusuf et al., 2000, NEJM (PMID 10639540)n=9541Large primary cardiovascular prevention trial. 400 IU/day natural vitamin E for over 4 years showed no reduction in cardiovascular events vs placebo. One of the first big trials to puncture the antioxidant cardiovascular hypothesis.
Used natural-source vitamin E rather than synthetic, addressing one common criticism. Result was unequivocally null at meaningful endpoints.
HOPE-TOO — long-term extension of HOPE
negative · RCT
Lonn et al., 2005, JAMA (PMID 15769967)n=7030Extended HOPE follow-up to 7 years. Still no cancer or cardiovascular benefit, and a worrying 19% increase in heart failure hospitalization in the vitamin E group. Reinforced that long-term high-dose vitamin E does not help and may hurt cardiovascular outcomes.
Heart failure signal raised concern that vitamin E could destabilize ventricular function in high-risk patients. Subsequent meta-analyses partially supported this concern.
GISSI-Prevenzione — vitamin E and omega-3 after MI
Null · RCT
GISSI-Prevenzione Investigators, 1999, Lancet (PMID 10465168)n=11324Large secondary prevention trial in post-MI patients. Vitamin E showed no reduction in death, MI, or stroke. The omega-3 arm of the same trial did show benefit — but vitamin E did not.
Italian post-MI population. Null result aligns with HOPE and the broader vitamin E cardiovascular literature.
Women's Health Study — vitamin E for cardiovascular events and cancer in women
Null · RCT
Lee et al., 2005, JAMA (PMID 15998891)n=39876Large 10-year primary prevention trial in healthy women. Alternate-day vitamin E showed no reduction in cardiovascular events or cancer. A small reduction in cardiovascular mortality in older subgroups was hypothesis-generating, not the primary finding.
Alternate-day dosing rather than daily. Generally healthy women. Adds to the consistent null cardiovascular and cancer prevention picture for vitamin E.
4 forms of Vitamin E compared
d-alpha-tocopherol (natural)
Higher serum levels per IU than synthetic form; preferred in trials with positive cardiovascular endpoints
Best forMost modern supplement formulations and trialsNatural-source vitamin E from vegetable oils. The form used in HOPE and the Women's Health Study (both null at meaningful endpoints despite using the natural form).
dl-alpha-tocopherol (synthetic, all-rac)
Approximately 50% the biological activity of natural d-alpha-tocopherol
Best forOlder formulations and SELECT trialSynthetic mixture of eight stereoisomers. Less bioactive than the natural form. Used in SELECT, where it increased prostate cancer.
Mixed tocopherols
Varies by formulation; gamma-tocopherol may have distinct biological effects
Best forPremium supplement formulationsIncludes alpha, beta, gamma, and delta tocopherols. Theoretical advantage from preserving gamma-tocopherol, which alpha-tocopherol supplementation lowers. Clinical-outcome evidence for mixed tocopherols is limited.
Tocotrienols
Distinct family of vitamin E compounds with shorter side chains; absorption requires fat
Best forSpecialty supplements for cholesterol or hepatic usesSeparate compounds from tocopherols, despite being part of the broader vitamin E family. Most outcome trial evidence is for alpha-tocopherol; tocotrienol clinical evidence is preliminary.
Are you deficient? Symptoms, risk groups, lab tests
Frank vitamin E deficiency is rare in healthy adults — under 1% in well-fed populations. Functional deficiency occurs almost exclusively in fat malabsorption disorders, abetalipoproteinemia, and ataxia with vitamin E deficiency (a rare genetic disorder).
Common symptoms
- Hemolytic anemia (especially in premature infants)
- Peripheral neuropathy with reduced position and vibration sense
- Ataxia and impaired coordination
- Skeletal myopathy with proximal weakness
- Retinopathy and pigmentary retinal changes
- Impaired immune response in deficient individuals
- In severe genetic deficiency: spinocerebellar syndrome with progressive neurological decline
Who is at risk
Adults with fat malabsorption disorders
Vitamin E is fat-soluble and absorption requires bile acids and pancreatic lipase. Cystic fibrosis, chronic pancreatitis, celiac disease, Crohn's, cholestatic liver disease, and bariatric surgery all impair absorption.
People with abetalipoproteinemia
This rare genetic disorder prevents formation of chylomicrons and VLDL, which are required for vitamin E transport. Affected individuals develop severe vitamin E deficiency without aggressive supplementation.
People with ataxia with vitamin E deficiency (AVED)
Genetic mutation in the alpha-tocopherol transfer protein impairs hepatic vitamin E secretion, causing progressive neurological decline that responds to high-dose vitamin E supplementation.
Premature infants
Limited prenatal vitamin E transfer plus immature fat absorption make premature newborns vulnerable to hemolytic anemia and retinopathy of prematurity.
Adults on long-term mineral oil or orlistat
These agents block absorption of fat-soluble vitamins.
Lab markers
Serum alpha-tocopherol
Reflects current intake; correlates with serum lipid levels, so should be interpreted relative to total cholesterol or expressed as a ratio.
Better:Alpha-tocopherol to total lipid ratio
- Frank deficiency
- <11.6 µmol/L (<5 µg/mL)
- Adequate
- 12–46 µmol/L
Side effects and drug interactions
Side effects
Increased prostate cancer in men
Severe · 400 IU/day or higher in men
Alpha-tocopherol at 400 IU/day increased prostate cancer incidence by 17% in men in the SELECT trial. Hard contraindication for men considering routine high-dose supplementation.
Increased all-cause mortality at high doses
Uncommon · 400 IU/day or higher
Miller 2005 meta-analysis of 19 trials linked vitamin E at 400 IU/day or higher to a 4% increase in all-cause mortality. Bjelakovic 2007 confirmed the directional signal.
Increased bleeding risk
Uncommon · Above 400 IU/day, especially with anticoagulants
Vitamin E inhibits platelet aggregation and may potentiate bleeding, especially when combined with anticoagulants. ATBC and HOPE-TOO showed signals consistent with elevated hemorrhagic stroke and heart failure.
Increased heart failure hospitalization
Uncommon · 400 IU/day in cardiovascular high-risk populations
HOPE-TOO showed a 19% increase in heart failure hospitalization in high-risk cardiovascular patients on 400 IU/day natural vitamin E for 7 years.
Nausea, headache, fatigue
Uncommon
Mild GI and constitutional symptoms occasionally reported with high-dose vitamin E, particularly above 800 IU/day.
Hemorrhagic stroke
Rare
Pooled trial data raised concern for an increase in hemorrhagic stroke with high-dose vitamin E, although the absolute risk is small.
Drug interactions
Additive effect
warfarinapixabanrivaroxabandabigatranedoxabanaspirinclopidogrelVitamin E inhibits platelet aggregation and may amplify bleeding risk in combination with antithrombotic medications.
Avoid high-dose vitamin E (above 400 IU/day) while on anticoagulants or antiplatelet agents without prescriber input.
Reduces nutrient status
chemotherapy and radiotherapy (general)High-dose antioxidants including vitamin E may theoretically blunt the oxidative-damage mechanism of action of some chemotherapy and radiotherapy regimens. Evidence is mixed but oncologists generally advise against high-dose antioxidant supplementation during active cancer treatment.
Do not start high-dose vitamin E during cancer treatment without oncology team approval.
Reduces nutrient status
orlistatbile acid sequestrants (cholestyramine, colestipol)mineral oilThese agents impair fat-soluble vitamin absorption.
Separate vitamin E dosing from these drugs by at least 2 hours.
Other critical caveats
- Doses of 400 IU/day or higher are linked to increased all-cause mortality (Miller 2005 meta-analysis) and increased prostate cancer in men (SELECT 2011). The case for routine high-dose supplementation is refuted, not merely unproven.
- Combining high-dose vitamin E with anticoagulants or antiplatelet drugs raises bleeding risk. Do not stack high-dose vitamin E with warfarin, DOACs, aspirin, or clopidogrel without prescriber input.
- Cardiovascular high-risk patients on 400 IU/day natural vitamin E showed a 19% increase in heart failure hospitalization in HOPE-TOO. High-dose vitamin E is not a cardiovascular intervention and may worsen heart failure outcomes.
Frequently asked
Should I take vitamin E?
Probably not. Most adults get adequate vitamin E from nuts, seeds, and vegetable oils. Routine supplementation has failed in nearly every major prevention trial — HOPE, GISSI, the Women's Health Study, ATBC, SELECT — and at doses of 400 IU/day or higher is linked to a small increase in all-cause mortality. SELECT specifically showed a 17% increase in prostate cancer in men. Skip it for general use.What dose of vitamin E is safe?
The Recommended Dietary Allowance is 15 mg (22.5 IU natural / 33 IU synthetic) for adults. The Tolerable Upper Intake Level is 1,000 mg (1,500 IU natural / 2,200 IU synthetic) per day from supplemental sources. The mortality and prostate cancer signals show up at 400 IU/day or higher — well below the IOM upper limit. The cleanest answer is to get vitamin E from food and skip the supplement.Will vitamin E prevent heart disease?
No. HOPE (n=9,541), HOPE-TOO (7-year extension), GISSI-Prevenzione (n=11,324), and the Women's Health Study (n=39,876, 10 years) all randomized adults to vitamin E and found no reduction in cardiovascular events. HOPE-TOO showed a 19% increase in heart failure hospitalization. The cardiovascular hypothesis didn't survive contact with proper trials.Will vitamin E help my Alzheimer's risk?
Two trials (Sano 1997 and TEAM-AD 2014) at 2,000 IU/day modestly slowed functional decline in established mild-to-moderate Alzheimer's disease, but cognitive scores did not improve. The Petersen 2005 trial showed vitamin E does NOT prevent progression from mild cognitive impairment to AD. So: vitamin E does not prevent dementia, may be considered as adjunct in established AD under physician supervision, and has no role in cognition for healthy adults.Should I take natural or synthetic vitamin E?
If you supplement at all, natural d-alpha-tocopherol is the more bioactive form. But the natural form has been tested in HOPE and the Women's Health Study and was null on cardiovascular and cancer endpoints. Switching from synthetic to natural does not rescue the failed antioxidant hypothesis.
References
- 01NIH Office of Dietary Supplements — Vitamin E Health Professional Fact Sheet
- 02StatPearls — Vitamin E Deficiency (NCBI Bookshelf)
- 03StatPearls — Vitamin E Toxicity (NCBI Bookshelf)
Last reviewed2026-05-07